GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (NAS:THTX) » Definitions » EV-to-EBIT

Theratechnologies (Theratechnologies) EV-to-EBIT : -11.49 (As of Jun. 10, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Theratechnologies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Theratechnologies's Enterprise Value is $78.88 Mil. Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-6.87 Mil. Therefore, Theratechnologies's EV-to-EBIT for today is -11.49.

The historical rank and industry rank for Theratechnologies's EV-to-EBIT or its related term are showing as below:

THTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -302.28   Med: -11.04   Max: 720.18
Current: -11.61

During the past 13 years, the highest EV-to-EBIT of Theratechnologies was 720.18. The lowest was -302.28. And the median was -11.04.

THTX's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.8 vs THTX: -11.61

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Theratechnologies's Enterprise Value for the quarter that ended in Feb. 2024 was $87.36 Mil. Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-6.87 Mil. Theratechnologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -7.86%.


Theratechnologies EV-to-EBIT Historical Data

The historical data trend for Theratechnologies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies EV-to-EBIT Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.79 -12.22 -12.89 -6.07 -6.88

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.28 -4.80 -3.06 -6.88 -12.96

Competitive Comparison of Theratechnologies's EV-to-EBIT

For the Biotechnology subindustry, Theratechnologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theratechnologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theratechnologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Theratechnologies's EV-to-EBIT falls into.



Theratechnologies EV-to-EBIT Calculation

Theratechnologies's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=78.879/-6.868
=-11.49

Theratechnologies's current Enterprise Value is $78.88 Mil.
Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies  (NAS:THTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Theratechnologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2024 ) =EBIT / Enterprise Value (Q: Feb. 2024 )
=-6.868/87.358
=-7.86 %

Theratechnologies's Enterprise Value for the quarter that ended in Feb. 2024 was $87.36 Mil.
Theratechnologies's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Theratechnologies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (Theratechnologies) Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.